Published in Expert Rev Neurother on June 27, 2014
Pharmacology of cognitive enhancers for exposure-based therapy of fear, anxiety and trauma-related disorders. Pharmacol Ther (2014) 0.92
Behavior Therapy for Tic Disorders: An Evidenced-based Review and New Directions for Treatment Research. Curr Dev Disord Rep (2015) 0.86
Hunger Promotes Fear Extinction by Activation of an Amygdala Microcircuit. Neuropsychopharmacology (2015) 0.78
Bothersome tics in patients with chronic tic disorders: Characteristics and individualized treatment response to behavior therapy. Behav Res Ther (2015) 0.78
The effect of D-cycloserine on social anxiety treatment using a behavioral outcome measure and a post-session administration strategy. Behav Anal (Wash D C) (2016) 0.75
Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry (2005) 58.92
Cognitive behavioral therapy, sertraline, or a combination in childhood anxiety. N Engl J Med (2008) 10.48
The amygdala modulates the consolidation of memories of emotionally arousing experiences. Annu Rev Neurosci (2004) 7.75
Neurotrophin-regulated signalling pathways. Philos Trans R Soc Lond B Biol Sci (2006) 7.18
Genetic variant BDNF (Val66Met) polymorphism alters anxiety-related behavior. Science (2006) 5.89
Preventing the return of fear in humans using reconsolidation update mechanisms. Nature (2009) 5.82
Cognitive enhancers as adjuncts to psychotherapy: use of D-cycloserine in phobic individuals to facilitate extinction of fear. Arch Gen Psychiatry (2004) 5.26
A randomized, double-blind evaluation of D-cycloserine or alprazolam combined with virtual reality exposure therapy for posttraumatic stress disorder in Iraq and Afghanistan War veterans. Am J Psychiatry (2014) 4.25
The epidemiology of obsessive-compulsive disorder in the National Comorbidity Survey Replication. Mol Psychiatry (2008) 3.81
Cognitive behavioral therapy for posttraumatic stress disorder in women: a randomized controlled trial. JAMA (2007) 3.66
Cognitive-behavioral therapy for adult anxiety disorders: a meta-analysis of randomized placebo-controlled trials. J Clin Psychiatry (2008) 3.64
Augmentation of behavior therapy with D-cycloserine for obsessive-compulsive disorder. Am J Psychiatry (2008) 3.63
A genetic variant BDNF polymorphism alters extinction learning in both mouse and human. Science (2010) 3.61
Randomized, placebo-controlled trial of exposure and ritual prevention, clomipramine, and their combination in the treatment of obsessive-compulsive disorder. Am J Psychiatry (2005) 3.38
Different mechanisms of fear extinction dependent on length of time since fear acquisition. Learn Mem (2006) 3.30
TrkB signalling pathways in LTP and learning. Nat Rev Neurosci (2009) 3.12
D-cycloserine augmented exposure therapy for obsessive-compulsive disorder. Biol Psychiatry (2007) 3.03
Cognitive-behavioral therapy for anxiety disordered youth: a randomized clinical trial evaluating child and family modalities. J Consult Clin Psychol (2008) 2.91
Augmentation of exposure therapy with D-cycloserine for social anxiety disorder. Arch Gen Psychiatry (2006) 2.77
Enhanced memory for emotional material following stress-level cortisol treatment in humans. Psychoneuroendocrinology (2001) 2.23
Enhanced human memory consolidation with post-learning stress: interaction with the degree of arousal at encoding. Learn Mem (2003) 2.19
A meta-analysis of D-cycloserine and the facilitation of fear extinction and exposure therapy. Biol Psychiatry (2008) 2.17
A randomized placebo-controlled trial of D-cycloserine to enhance exposure therapy for posttraumatic stress disorder. Biol Psychiatry (2012) 2.12
Efficacy of d-cycloserine for enhancing response to cognitive-behavior therapy for panic disorder. Biol Psychiatry (2009) 2.09
A randomized controlled trial of D-cycloserine enhancement of exposure therapy for social anxiety disorder. Biol Psychiatry (2008) 2.03
D-Cycloserine as an augmentation strategy with cognitive-behavioral therapy for social anxiety disorder. Am J Psychiatry (2013) 1.94
Acute cortisone administration impairs retrieval of long-term declarative memory in humans. Nat Neurosci (2000) 1.90
Glucocorticoids and the regulation of memory in health and disease. Front Neuroendocrinol (2009) 1.85
Induction of c-Fos expression in specific areas of the fear circuitry in rat forebrain by anxiogenic drugs. Biol Psychiatry (2003) 1.79
D-cycloserine and the facilitation of extinction of conditioned fear: consequences for reinstatement. Behav Neurosci (2004) 1.75
Glucocorticoids reduce phobic fear in humans. Proc Natl Acad Sci U S A (2006) 1.64
Temporally massed CS presentations generate more fear extinction than spaced presentations. J Exp Psychol Anim Behav Process (2003) 1.62
Disrupting reconsolidation: pharmacological and behavioral manipulations. Learn Mem (2011) 1.58
Memory modulation. Behav Neurosci (2011) 1.57
The brain-derived neurotrophic factor Val66Met polymorphism predicts response to exposure therapy in posttraumatic stress disorder. Biol Psychiatry (2013) 1.54
A randomized placebo-controlled trial of D-cycloserine and exposure therapy for posttraumatic stress disorder. J Psychiatr Res (2012) 1.50
Variant BDNF Val66Met polymorphism affects extinction of conditioned aversive memory. J Neurosci (2009) 1.46
D-cycloserine does not enhance exposure-response prevention therapy in obsessive-compulsive disorder. Int Clin Psychopharmacol (2007) 1.46
A randomized controlled trial of the effect of D-cycloserine on exposure therapy for spider fear. J Psychiatr Res (2006) 1.44
Low-dose cortisol for symptoms of posttraumatic stress disorder. Am J Psychiatry (2004) 1.40
Yohimbine challenge in children with anxiety disorders. Am J Psychiatry (2000) 1.40
Effectiveness of psychological and pharmacological treatments for obsessive-compulsive disorder: a quantitative review. J Consult Clin Psychol (1997) 1.36
Variant brain-derived neurotrophic factor Val66Met endophenotypes: implications for posttraumatic stress disorder. Ann N Y Acad Sci (2010) 1.35
Glucocorticoids enhance extinction-based psychotherapy. Proc Natl Acad Sci U S A (2011) 1.33
Fear extinction and BDNF: translating animal models of PTSD to the clinic. Genes Brain Behav (2012) 1.31
Controlled comparison of family cognitive behavioral therapy and psychoeducation/relaxation training for child obsessive-compulsive disorder. J Am Acad Child Adolesc Psychiatry (2011) 1.29
Extinction during reconsolidation of threat memory diminishes prefrontal cortex involvement. Proc Natl Acad Sci U S A (2013) 1.27
The BDNF Val66Met polymorphism impairs NMDA receptor-dependent synaptic plasticity in the hippocampus. J Neurosci (2010) 1.26
D-cycloserine enhancement of fear extinction is specific to successful exposure sessions: evidence from the treatment of height phobia. Biol Psychiatry (2013) 1.26
Yohimbine: a clinical review. Pharmacol Ther (2001) 1.21
A preliminary study of D-cycloserine augmentation of cognitive-behavioral therapy in pediatric obsessive-compulsive disorder. Biol Psychiatry (2010) 1.20
Relationship of enhanced norepinephrine activity during memory consolidation to enhanced long-term memory in humans. Am J Psychiatry (2002) 1.18
D-cycloserine augmentation of exposure therapy for post-traumatic stress disorder: a pilot randomized clinical trial. Neuropsychopharmacology (2013) 1.18
Need for speed: evaluating slopes of OCD recovery in behavior therapy enhanced with d-cycloserine. Behav Res Ther (2010) 1.18
Pharmacological facilitation of fear extinction and the search for adjunct treatments for anxiety disorders--the case of yohimbine. Trends Pharmacol Sci (2009) 1.17
NMDA receptors and fear extinction: implications for cognitive behavioral therapy. Dialogues Clin Neurosci (2011) 1.17
BDNF Val66Met impairs fluoxetine-induced enhancement of adult hippocampus plasticity. Neuropsychopharmacology (2012) 1.16
Preventive effect of beta-adrenoceptor blockade on glucocorticoid-induced memory retrieval deficits. Am J Psychiatry (2007) 1.15
The use of cognitive enhancers in animal models of fear extinction. Pharmacol Biochem Behav (2011) 1.15
The NMDA agonist D-cycloserine facilitates fear memory consolidation in humans. Cereb Cortex (2008) 1.13
Symptom dimensions in obsessive-compulsive disorder: prediction of cognitive-behavior therapy outcome. Acta Psychiatr Scand (2006) 1.12
Can fear extinction be enhanced? A review of pharmacological and behavioral findings. Brain Res Bull (2013) 1.09
Noradrenergic modulation of extinction learning and exposure therapy. Behav Brain Res (2009) 1.08
Stimulation of the noradrenergic system enhances and blockade reduces memory for emotional material in man. Psychol Med (1999) 1.07
Deepened extinction following compound stimulus presentation: noradrenergic modulation. Learn Mem (2010) 1.07
Development of a patient adherence scale for exposure and response prevention therapy. Behav Ther (2009) 1.06
Augmentation of exposure therapy with post-session administration of D-cycloserine. J Psychiatr Res (2012) 1.06
D-cycloserine does not improve but might slightly speed up the outcome of in-vivo exposure therapy in patients with severe agoraphobia and panic disorder in a randomized double blind clinical trial. J Psychiatr Res (2011) 1.06
Mood changes in response to psychosocial stress in healthy young women: effects of pretreatment with cortisol. Behav Neurosci (2007) 1.05
Treatment attrition during group therapy for social phobia. J Anxiety Disord (2006) 1.02
SSRI adverse events: how to monitor and manage. Int Rev Psychiatry (2008) 1.01
Glucocorticoid receptor activation in the rat nucleus of the solitary tract facilitates memory consolidation: involvement of the basolateral amygdala. Eur J Neurosci (1999) 0.98
D-Cycloserine as an augmentation strategy for cognitive behavioral therapy of anxiety disorders. Biol Mood Anxiety Disord (2013) 0.98
Memory facilitating and anti-amnesic effects of corticosteroids. Pharmacol Biochem Behav (1978) 0.96
Facilitation of fear extinction in phobic participants with a novel cognitive enhancer: a randomized placebo controlled trial of yohimbine augmentation. J Anxiety Disord (2009) 0.96
Noradrenergic enhancement of associative fear memory in humans. Neurobiol Learn Mem (2011) 0.95
D-cycloserine augmentation of behavioral therapy for the treatment of anxiety disorders: a meta-analysis. J Clin Psychiatry (2012) 0.95
Glucocorticoid therapy-induced memory deficits: acute versus chronic effects. J Neurosci (2008) 0.93
Critical parameters for D-cycloserine enhancement of cognitive-behaviorial therapy for obsessive-compulsive disorder. Am J Psychiatry (2008) 0.92
Glucocorticoids enhance in vivo exposure-based therapy of spider phobia. Depress Anxiety (2013) 0.90
Involvement of NMDA receptors within the amygdala in short- versus long-term memory for fear conditioning as assessed with fear-potentiated startle. Behav Neurosci (2000) 0.90
Exposure therapy, D-cycloserine, and functional magnetic resonance imaging in patients with snake phobia: a randomized pilot study. J Clin Psychiatry (2012) 0.90
Randomized placebo-controlled D-cycloserine with cognitive behavior therapy for pediatric posttraumatic stress. J Child Adolesc Psychopharmacol (2014) 0.89
Variation in the BDNF Val66Met polymorphism and response to cognitive-behavior therapy in obsessive-compulsive disorder. Eur Psychiatry (2011) 0.89
Serum brain-derived neurotrophic factor (BDNF) levels in patients with panic disorder: as a biological predictor of response to group cognitive behavioral therapy. Prog Neuropsychopharmacol Biol Psychiatry (2005) 0.88
Yohimbine enhancement of exposure therapy for social anxiety disorder: a randomized controlled trial. Biol Psychiatry (2013) 0.88
Pharmacological enhancement of exposure-based treatment in PTSD: a qualitative review. Eur J Psychotraumatol (2013) 0.88
Randomized, placebo-controlled trial of cognitive-behavioral therapy alone or combined with sertraline in the treatment of pediatric obsessive-compulsive disorder. Behav Res Ther (2013) 0.87
The nature, assessment, and treatment of obsessive-compulsive disorder. Postgrad Med (2012) 0.86
Difficult-to-treat pediatric obsessive-compulsive disorder: feasibility and preliminary results of a randomized pilot trial of D-cycloserine-augmented behavior therapy. Depress Anxiety (2013) 0.85
Cognitive-behavioural therapy with post-session D-cycloserine augmentation for paediatric obsessive-compulsive disorder: pilot randomised controlled trial. Br J Psychiatry (2013) 0.84
The need for expanded monitoring of adverse events in behavioral health clinical trials. Contemp Clin Trials (2012) 0.84
Symptom dimensions and cognitive-behavioural therapy outcome for pediatric obsessive-compulsive disorder. Acta Psychiatr Scand (2007) 0.83
Serum brain-derived neurotrophic factor predicts responses to escitalopram in chronic posttraumatic stress disorder. Prog Neuropsychopharmacol Biol Psychiatry (2010) 0.83
Dysregulation in pediatric obsessive compulsive disorder. Psychiatry Res (2013) 0.82
Does yohimbine hydrochloride facilitate fear extinction in virtual reality treatment of fear of flying? A randomized placebo-controlled trial. Psychother Psychosom (2011) 0.81
Neuropsychological performance across symptom dimensions in pediatric obsessive compulsive disorder. Depress Anxiety (2014) 0.80
Treatment of posttraumatic stress disorder in children and adolescents. Curr Opin Psychiatry (2013) 0.79
Advances in the treatment of pediatric obsessive-compulsive d-cycloserine with exposure and response prevention. Neuropsychiatry (London) (2012) 0.79
Does d-Cycloserine Augmentation of CBT Improve Therapeutic Homework Compliance for Pediatric Obsessive-Compulsive Disorder? J Child Fam Stud (2014) 0.79
The relation between family factors and metabolic control: the role of diabetes adherence. J Pediatr Psychol (2005) 2.00
Validity and reliability of an adolescent and parent rating scale of type 1 diabetes adherence behaviors: the Self-Care Inventory (SCI). J Pediatr Psychol (2009) 1.80
Peer victimization, psychosocial adjustment, and physical activity in overweight and at-risk-for-overweight youth. J Pediatr Psychol (2006) 1.70
Rage attacks in pediatric obsessive-compulsive disorder: phenomenology and clinical correlates. J Am Acad Child Adolesc Psychiatry (2012) 1.69
Glycemic control in youth with type 1 diabetes: family predictors and mediators. J Pediatr Psychol (2008) 1.67
Decreased family accommodation associated with improved therapy outcome in pediatric obsessive-compulsive disorder. J Consult Clin Psychol (2009) 1.44
Correlates of comorbid anxiety and externalizing disorders in childhood obsessive compulsive disorder. Eur Child Adolesc Psychiatry (2010) 1.31
Skin picking behaviors: An examination of the prevalence and severity in a community sample. J Anxiety Disord (2009) 1.30
Trichotillomania: A current review. Clin Psychol Rev (2009) 1.30
Defining treatment response and remission in obsessive-compulsive disorder: a signal detection analysis of the Children's Yale-Brown Obsessive Compulsive Scale. J Am Acad Child Adolesc Psychiatry (2010) 1.29
Behavioral treatment of self-injury, 1964 to 2000. Am J Ment Retard (2002) 1.25
The effect of cognitive-behavioral therapy versus treatment as usual for anxiety in children with autism spectrum disorders: a randomized, controlled trial. J Am Acad Child Adolesc Psychiatry (2013) 1.23
A preliminary study of D-cycloserine augmentation of cognitive-behavioral therapy in pediatric obsessive-compulsive disorder. Biol Psychiatry (2010) 1.20
Assessment of obsessive-compulsive symptom dimensions: development and evaluation of the Dimensional Obsessive-Compulsive Scale. Psychol Assess (2010) 1.20
Refining clinical judgment of treatment outcome in obsessive-compulsive disorder. Psychiatry Res (2010) 1.18
The children's Yale-Brown obsessive-compulsive scale: psychometric properties of child- and parent-report formats. J Anxiety Disord (2006) 1.16
Clinical predictors of response to cognitive-behavioral therapy for obsessive-compulsive disorder. Clin Psychol Rev (2007) 1.15
Maternal efforts to prevent type 1 diabetes in at-risk children. Diabetes Care (2005) 1.15
Clinical factors associated with pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections. J Pediatr (2011) 1.14
Preliminary investigation of web-camera delivered cognitive-behavioral therapy for youth with obsessive-compulsive disorder. Psychiatry Res (2011) 1.10
Design considerations related to short-term psychodynamic psychotherapy. J Am Acad Child Adolesc Psychiatry (2013) 1.09
Letter: Evaluating Risks and Benefit of Deep Brain Stimulation for Treatment-Refractory Tourette Syndrome. Neurosurgery (2016) 1.07
Home-based behavioral health intervention: Use of a telehealth model to address poor adherence to type-1 diabetes medical regimens. Telemed J E Health (2006) 1.04
A structural equation analysis of family accommodation in pediatric obsessive-compulsive disorder. J Abnorm Child Psychol (2012) 1.02
The psychometric properties of the Brief Fear of Negative Evaluation Scale. J Anxiety Disord (2005) 1.02
SSRI adverse events: how to monitor and manage. Int Rev Psychiatry (2008) 1.01
Multiple informant agreement on the anxiety disorders interview schedule in youth with autism spectrum disorders. J Child Adolesc Psychopharmacol (2012) 1.01
Cefdinir for recent-onset pediatric neuropsychiatric disorders: a pilot randomized trial. J Child Adolesc Psychopharmacol (2014) 1.01
Risk of adverse behavioral effects with pediatric use of antidepressants. Psychopharmacology (Berl) (2006) 1.01
Quality of life in children and adolescents with obsessive-compulsive disorder: base rates, parent-child agreement, and clinical correlates. Soc Psychiatry Psychiatr Epidemiol (2009) 1.00
Defining treatment response in pediatric tic disorders: a signal detection analysis of the Yale Global Tic Severity Scale. J Child Adolesc Psychopharmacol (2011) 1.00
Practice parameter for the assessment and treatment of children and adolescents with tic disorders. J Am Acad Child Adolesc Psychiatry (2013) 0.99
Brief report: exposure and response prevention for obsessive compulsive disorder in a 12-year-old with autism. J Autism Dev Disord (2008) 0.98
Telehealth behavior therapy for the management of type 1 diabetes in adolescents. J Diabetes Sci Technol (2010) 0.98
Further psychometric support for the Sensation Seeking Scale--Form V. J Pers Assess (2003) 0.96
Evidence-based assessment of compulsive skin picking, chronic tic disorders and trichotillomania in children. Child Psychiatry Hum Dev (2012) 0.96
Step one within stepped care trauma-focused cognitive behavioral therapy for young children: a pilot study. Child Psychiatry Hum Dev (2014) 0.95
Multiple pathways to functional impairment in obsessive-compulsive disorder. Clin Psychol Rev (2010) 0.95
Hope and coping in family members of patients with obsessive-compulsive disorder. J Anxiety Disord (2005) 0.95
Development and preliminary psychometric evaluation of the Children's Saving Inventory. Child Psychiatry Hum Dev (2011) 0.94
Convergent and discriminant validity of the Children's Yale-Brown Obsessive Compulsive Scale-Symptom Checklist. J Anxiety Disord (2008) 0.93
Peer victimization in children with attention-deficit hyperactivity disorder. J Child Health Care (2007) 0.93
A neuropsychiatric review of pediatric obsessive-compulsive disorder: etiology and efficacious treatments. Neuropsychiatr Dis Treat (2006) 0.92
The status of hoarding as a symptom of obsessive-compulsive disorder. Behav Res Ther (2008) 0.92
Relationship of movements and behaviors to Group A Streptococcus infections in elementary school children. Biol Psychiatry (2006) 0.92
Disease-related stress in parents of children who are overweight: relations with parental anxiety and childhood psychosocial functioning. J Child Health Care (2007) 0.91
The Liebowitz social anxiety scale for children and adolescents: an initial psychometric investigation. J Am Acad Child Adolesc Psychiatry (2003) 0.90
Brief report: normative data on a structured interview for diabetes adherence in childhood. J Pediatr Psychol (2009) 0.90
The phenomenology of hairpulling in a community sample. J Anxiety Disord (2009) 0.89
Development and Psychometric Evaluation of the Treatment-Emergent Activation and Suicidality Assessment Profile. Child Youth Care Forum (2010) 0.89
Evidence-Based Assessment of Child Obsessive Compulsive Disorder: Recommendations for Clinical Practice and Treatment Research. Child Youth Care Forum (2010) 0.89
Obsessive-compulsive disorder with comorbid major depression: what is the role of cognitive factors? Behav Res Ther (2007) 0.88
Assessment of obsessive-compulsive disorder: a review. J Anxiety Disord (2007) 0.88
Convergent and discriminant validity and reliability of the pediatric anxiety rating scale in youth with autism spectrum disorders. J Autism Dev Disord (2012) 0.88
The role of comorbid disruptive behavior in the clinical expression of pediatric obsessive-compulsive disorder. Behav Res Ther (2010) 0.88
Randomized, placebo-controlled trial of cognitive-behavioral therapy alone or combined with sertraline in the treatment of pediatric obsessive-compulsive disorder. Behav Res Ther (2013) 0.87
Telehealth intervention for adolescents with type 1 diabetes. J Pediatr (2006) 0.87
The role of co-occurring disruptive behavior in the clinical presentation of children and adolescents with anxiety in the context of autism spectrum disorders. Child Psychiatry Hum Dev (2012) 0.87
Peer victimization in children with obsessive-compulsive disorder: relations with symptoms of psychopathology. J Clin Child Adolesc Psychol (2006) 0.86
The nature, assessment, and treatment of obsessive-compulsive disorder. Postgrad Med (2012) 0.86
Further psychometric analysis of the Florida Obsessive-Compulsive Inventory. J Anxiety Disord (2008) 0.86
The roles of anxiety and depression in connecting tic severity and functional impairment. J Anxiety Disord (2011) 0.86
Characterization of the pediatric acute-onset neuropsychiatric syndrome phenotype. J Child Adolesc Psychopharmacol (2014) 0.86
Hoarding behaviors among nonclinical elderly adults: correlations with hoarding cognitions, obsessive-compulsive symptoms, and measures of general psychopathology. J Anxiety Disord (2011) 0.86
A phenomenological investigation of women with Tourette or other chronic tic disorders. Compr Psychiatry (2011) 0.86
Psychometric properties of the obsessive compulsive inventory: child version in children and adolescents with obsessive-compulsive disorder. Child Psychiatry Hum Dev (2013) 0.86
Open label aripiprazole in the treatment of youth with tic disorders. J Child Adolesc Psychopharmacol (2009) 0.85
Difficult-to-treat pediatric obsessive-compulsive disorder: feasibility and preliminary results of a randomized pilot trial of D-cycloserine-augmented behavior therapy. Depress Anxiety (2013) 0.85
Quality of life in obsessive-compulsive disorder: the role of mediating variables. Psychiatry Res (2012) 0.85
Factors associated with poor response in cognitive-behavioral therapy for pediatric obsessive-compulsive disorder. Bull Menninger Clin (2010) 0.85
Variations in symptom prevalence and clinical correlates in younger versus older youth with obsessive-compulsive disorder. Child Psychiatry Hum Dev (2014) 0.84
Obsessive-compulsive disorder in Tourette syndrome. J Child Neurol (2006) 0.84
Cognitive behavioral therapy plus motivational interviewing improves outcome for pediatric obsessive-compulsive disorder: a preliminary study. Cogn Behav Ther (2010) 0.84
The therapeutic alliance in the cognitive behavioral treatment of pediatric obsessive-compulsive disorder. J Anxiety Disord (2011) 0.84
Perfectionism and peer relations among children with obsessive-compulsive disorder. Child Psychiatry Hum Dev (2008) 0.84
Perceptions of type 1 diabetes among affected youth and their peers. J Clin Psychol Med Settings (2009) 0.83
Compulsive hoarding in children. J Clin Psychol (2011) 0.83
Victimization of youth with type-1 diabetes by teachers: relations with adherence and metabolic control. J Child Health Care (2008) 0.83
Social deficits in children with chronic tic disorders: phenomenology, clinical correlates and quality of life. Compr Psychiatry (2013) 0.83
The phenomenology and clinical correlates of suicidal thoughts and behaviors in youth with autism spectrum disorders. J Autism Dev Disord (2013) 0.83
Behavioral treatment of a child with PANDAS. J Am Acad Child Adolesc Psychiatry (2004) 0.82
Current directions in pediatric obsessive-compulsive disorder. Pediatr Ann (2005) 0.82
Bullying, regimen self-management, and metabolic control in youth with type I diabetes. J Pediatr (2006) 0.82
Does cognitive-behavioral therapy response among adults with obsessive-compulsive disorder differ as a function of certain comorbidities? J Anxiety Disord (2010) 0.82
Parent-led, therapist-assisted, first-line treatment for young children after trauma: a case study. Child Maltreat (2011) 0.82
Psychometric properties of the Treatment-Emergent Activation and Suicidality Assessment Profile (TEASAP) in youth with OCD. Psychiatry Res (2012) 0.82